$2.55T
Total marketcap
$183.1B
Total volume
BTC 50.05%     ETH 15.87%
Dominance

Blueprint Medicines BPMC Stock

86.82 USD {{ price }} -4.066299% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
5.32B USD
LOW - HIGH [24H]
86.1 - 91.67 USD
VOLUME [24H]
970.88K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-8.37 USD

Blueprint Medicines Price Chart

Blueprint Medicines BPMC Financial and Trading Overview

Blueprint Medicines stock price 86.82 USD
Previous Close 58.76 USD
Open 58.19 USD
Bid 0 USD x 1100
Ask 0 USD x 1400
Day's Range 57.68 - 61 USD
52 Week Range 37.82 - 79.4 USD
Volume 582.59K USD
Avg. Volume 568.35K USD
Market Cap 3.68B USD
Beta (5Y Monthly) 0.704929
PE Ratio (TTM) N/A
EPS (TTM) -8.37 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 73.18 USD

BPMC Valuation Measures

Enterprise Value 3.1B USD
Trailing P/E N/A
Forward P/E -7.8669252
PEG Ratio (5 yr expected) 0.07
Price/Sales (ttm) 17.99608
Price/Book (mrq) 8.879976
Enterprise Value/Revenue 15.152
Enterprise Value/EBITDA -5.718

Trading Information

Blueprint Medicines Stock Price History

Beta (5Y Monthly) 0.704929
52-Week Change 25.21%
S&P500 52-Week Change 20.43%
52 Week High 79.4 USD
52 Week Low 37.82 USD
50-Day Moving Average 52.93 USD
200-Day Moving Average 50.85 USD

BPMC Share Statistics

Avg. Volume (3 month) 568.35K USD
Avg. Daily Volume (10-Days) 719.06K USD
Shares Outstanding 60.47M
Float 59.92M
Short Ratio 5.88
% Held by Insiders 0.74%
% Held by Institutions 107.34%
Shares Short 3.69M
Short % of Float 8.25%
Short % of Shares Outstanding 6.11%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -284.018%
Operating Margin (ttm) -271.72%
Gross Margin 88.81%
EBITDA Margin -264.98%

Management Effectiveness

Return on Assets (ttm) -29.39%
Return on Equity (ttm) -89.67%

Income Statement

Revenue (ttm) 204.59M USD
Revenue Per Share (ttm) 3.42 USD
Quarterly Revenue Growth (yoy) 0.89%
Gross Profit (ttm) 177.28M USD
EBITDA -542129984 USD
Net Income Avi to Common (ttm) -581078016 USD
Diluted EPS (ttm) -10.26
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 822.16M USD
Total Cash Per Share (mrq) 13.6 USD
Total Debt (mrq) 240.34M USD
Total Debt/Equity (mrq) 58.01 USD
Current Ratio (mrq) 5.214
Book Value Per Share (mrq) 6.857

Cash Flow Statement

Operating Cash Flow (ttm) -492512000 USD
Levered Free Cash Flow (ttm) -221860880 USD

Profile of Blueprint Medicines

Country United States
State MA
City Cambridge
Address 45 Sidney Street
ZIP 02139
Phone 617 374 7580
Website https://www.blueprintmedicines.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 651

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Q&A For Blueprint Medicines Stock

What is a current BPMC stock price?

Blueprint Medicines BPMC stock price today per share is 86.82 USD.

How to purchase Blueprint Medicines stock?

You can buy BPMC shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Blueprint Medicines?

The stock symbol or ticker of Blueprint Medicines is BPMC.

Which industry does the Blueprint Medicines company belong to?

The Blueprint Medicines industry is Biotechnology.

How many shares does Blueprint Medicines have in circulation?

The max supply of Blueprint Medicines shares is 61.23M.

What is Blueprint Medicines Price to Earnings Ratio (PE Ratio)?

Blueprint Medicines PE Ratio is now.

What was Blueprint Medicines earnings per share over the trailing 12 months (TTM)?

Blueprint Medicines EPS is -8.37 USD over the trailing 12 months.

Which sector does the Blueprint Medicines company belong to?

The Blueprint Medicines sector is Healthcare.

Blueprint Medicines BPMC included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Nasdaq US 700 Small Cap Value N NQUS700SCVN 2257.06 USD
-0.73
2256.98 USD 2273.86 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
Nasdaq US 700 Small Cap Value I NQUS700SCV 2033.66 USD
-0.73
2033.59 USD 2048.8 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD